Collecting Duct Carcinoma Of Kidney Research Articles

Collecting duct carcinoma of kidney in a teenage boy

Carcinoma of the collecting ducts of Bellini are rare aggressive neoplasms of distal nephron origin; it accounts for 2% of all renal cell carcinomas. Clinically, collecting duct carcinoma (CDC) is characterized by an extremely aggressive phenotype, accompanying metastatic diseases at presentation in most reported cases. Most cases of CDC have been reported with median age above 50 years. To our knowledge, this is the only second case report of CDC in a young teenager patient below 19 years with metastasis to lungs and bones at presentation.

Collecting Duct Carcinoma of Kidney

Collecting duct carcinoma is a rare renal neoplasm that originates from the distal segment of the collecting duct in the renal medulla pyramids. Of all renal epithelial neoplasms, collecting duct carcinoma is the most aggressive, showing early metastatic behavior, poor prognosis, and limited response to immunotherapy. Recently, chemotherapy regimens commonly used for urothelial carcinoma have been demonstrated to be superior to the ones used for renal cell carcinoma in patients affected by this malignancy. Therefore, distinction between collecting duct carcinoma and other renal neoplasms involving renal medulla is desirable.

Collecting duct carcinoma of kidney producing alpha-fetoprotein

Aim A case of a collecting duct carcinoma (CDC) of the kidney alpha-fetoprotein producing is reported. Serum elevation of alpha-fetoprotein (AFP) is a common marker for hepatocellular carcinoma, although some extrahepatic carcinomas, also of the kidney, with elevated AFP levels have also been reported in the literature. Case report A 62-year-old man with a collecting duct carcinoma of the kidney presenting as a mediastinal mass and supra-clavicular lymph node enlargement, and with a serum alpha-fetoprotein (AFP) level of 102.8 μg/L. Results and conclusions CDC of the kidney is associated with an aggressive course and extremely poor prognosis. There are no standard treatment regimens, and neither immunotherapy nor chemotherapy has been found to be effective. In the present case, nephrectomy followed by a chemotherapeutic association of carboplatin and gemcitabine gave promising results, with lessening of the patient's symptoms.